Sun boss: staff empowerment, integrity key for compliance
This article was originally published in Scrip
As some frontline Indian firms grapple with GMP (good manufacturing practice) compliance issues at plants servicing the US market, the generally reticent chief of Sun Pharmaceutical Industries, Dilip Shanghvi, has underscored the importance of people empowerment and integrity in the production process and "compliance with 24/7 readiness" at plants worldwide.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.